NASDAQ · BBNX

Beta Bionics, Inc.

$15.85 -$0.28 (-1.74%) 1D After hours

Key Metrics

$718.78M
Market cap
P/E · TTM
$110.24M
Revenue · TTM
−$66.44M
Net income
EPS · TTM $-2.16
Dividend yield
Free cash flow −$61.12M
Beta · 1Y 1.23
EBITDA · TTM −$75.46M
Gross margin 57.2%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 4
    The stock moved +11.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 4
  • Apr 13
    The stock moved +20.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 13
  • Apr 10
    From its Jan 29 high, the share price fell 40%.

    Peak close $14.79 on Jan 29; trough close $8.86 on Apr 10. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -40%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$718.78M
Enterprise value
Shares outstanding44.6M
52-wk range$8.80 – $32.71
Avg volume · 20D839.7K
Net cash
Book value / share$8.83
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Beta Bionics, Inc.
IPO dateJan 30, 2025
Employees423

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the trea…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S6.52
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 57.2%
Operating -70.1%
Net -60.3%
FCF -55.4%
ROE / ROIC -513.3% · —

Financial Health

Current ratio10.69
Quick ratio9.67
Debt / equity
Debt / EBITDA
Net cash
Working capital$224.80M

Cash Flow · TTM

Operating CF −$54.78M
Capex −$6.34M
Free cash flow −$61.12M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

11.6
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings